Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.
Sign Up to like & getrecommendations! Published in 2018 at "Biochimie"
DOI: 10.1016/j.biochi.2018.07.018
Abstract: Multiple laboratory evidences indicate that distinct variants of ALK translocations differ in their biochemical properties and responsiveness to ALK tyrosine kinase inhibitors (TKIs). These data are supported by some clinical studies, which showed improved responses… read more here.
Keywords: alk inhibitors; alk fusion; alk; fusion variants ... See more keywords
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.09.012
Abstract: OBJECTIVES The molecular profiles and prognosis of anaplastic lymphoma kinase (ALK) fusion and resectable non-small cell lung cancer (NSCLC) remain unclear. This study aimed to explore the distribution of ALK fusion variants and prognostic factors… read more here.
Keywords: alk fusion; alk; fusion variants; lung cancer ... See more keywords
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdw693
Abstract: Background Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like… read more here.
Keywords: alk inhibitors; alk; fusion variants; advanced alk ... See more keywords